Reports
Global Cervical Cancer Treatment Market Share, Size, Analysis, Forecast: By Stage: Stage 0, Stage 1, Stage 2, Stage 3, Stage 4; By Tests: Pap Smear Test Procedure, Colposcopy Procedure, ECC Procedure, Others; By Cell Type: Adenocarcinoma, Others; By Product Type; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Cervical Cancer Treatment Market Outlook
The global cervical cancer treatment market attained a value of USD 6.8 billion in 2022. The market is expected to grow further at a CAGR of 6.4% during the forecast period of 2023-2031 to attain a value of USD 12 billion by 2031, driven by the rising prevalence of the disease across the globe.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cervical Cancer Treatment Market: Introduction
Cervical cancer is the type of cancer that starts in the cervix, which is a part that connects the vagina to the uterus. Women over the age of thirty are more vulnerable to the risk of cervical cancer. Cervical cancer mostly happens to women who are sexually active and is caused due to the transmission of a virus called human papillomavirus (HPV) during sexual activities. While most of the women the virus at some point of their lives, only some of those women get cervical cancer. The virus does not show any significant symptoms, so the chances are that women who have it, would not even know. It only becomes a problem when it stay for a longer period and leads to the development of cancer cells in the cervical. Other than this virus, other factors that lead to higher chances of cervical cancer include HIV and tobacco consumption.
The main diagnostic methods for the disease include HPV vaccine and screening tests and the early the tests are done, the higher is the chance of survival. Although the cancer is easily treatable, it needs to be detected as early as possible for effective treatment, that ensures that the patient can lead a healthy life after the treatment. The possibility of recurrence is also less if the treatment is done well. The most effective way of preventing the possibility of having cervical cancer is to get HPV vaccine to minimise or eradicate the chances of cervical, vulvar, and vaginal cancers. These vaccinations can be taken in different age groups and can be started from as early as 9 years. If not as early as 9 years, this vaccine can also be taken in the older age with doctor’s advice in different shots. The chances of prevention, however, decrease as the person ages without the vaccination. Moreover, the vaccine can also reduce the chances of tumours in the future and not treat any existing tumour in the body. For this reason, it is important to get regular screening done in order to detect any existing cancer.
Common symptoms of cervical cancer include the following:
- Watery/ Bloody Vaginal Discharge- This discharge could be thick and have a foul smell.
- Vaginal Bleeding – During or after intercourse, during menstruation cycles, or even after menopause.
- Menstruation Cycles- It could be painful and might last longer, the flow might be heavier.
In case the cancer spreads to other tissues or organs, the symptoms can get worse. The severe symptoms would include painful urination, presence of blood in urine, pain in rectum or bleeding in rectum. Other symptoms can be fatigue, loss of appetite, severe weight loss, perennial backache, swelling in the legs, pain in pelvic or abdominal region, among others.
Diagnostic Methods in the Cervical Cancer Treatment Market
These are two major diagnostic methods in the market currently:
The Pap Test/ Pap Smear- This test helps in identifying precancers or cancer cells that start developing in the cervical. In the test, cells are collected from the cervix to detect cancer in the cervix. The early detection of the cancer helps in getting early treatment. It is recommended for women to get these tests done every three years between the age group of 21-65.
HPV Test- This test detects the presence of HPV virus in the cervix and can help reduce the chances of getting cervical cancer if the virus is killed at the initial stage only.
Cervical Cancer Treatment Market Segmentations
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The cervical cancer treatment market can be categorised into segments like stage, tests, cell type, product type, treatment channels, and regions.
Market Breakup by Stage
- Stage 0
- Stage 1
- Stage 2
- Stage 3
- Stage 4
Market Breakup by Tests
- Pap Smear Test Procedure
- Colposcopy Procedure
- ECC Procedure
- Others
Market Breakup by Cell Type
- Adenocarcinoma
- Squamous Cell Carcinoma
- Adenosquamous Carcinoma
Market Breakup by Product Type
- Gardasil/Gardasil 9
- Cervarix
- Avastin
- Keytruda
- Generics
- Others
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cervical Cancer Treatment Market- Epidemiology
Cervical cancer is among the leading types of cancer amongst women. In 2020, the number of cervical cancer cases was close to 604000 and the death rate reached 342000. According to the estimates by American Cancer Society, nearly 13,960 more cases of cervical cancer will be diagnosed in 2023 and the death toll will reach close to 4,310 by 2023. Earlier, the number of deaths due to cervical cancer was extremely high in the United States but the numbers have now reduced significantly reduced due to the rising use of available tests like Pap test and HPV test due to the rising awareness.
The prevalence of cervical cancer is highest amongst older women, especially in the age group of 35-45. The possibility of having cervical cancer increases with age, about 20% of women are diagnosed with cancer when they are over the age of 65. Women under the age of 20 are less vulnerable to the disease.
Cervical Cancer Treatment Market- Therapeutic Landscape
Cervical cancer can be efficiently treated, if diagnosed early. The current treatment methods for cervical cancer include the following methods:
Radiation Therapy- This therapy uses beams or radiations to eliminate the cancer cells, The two therapies included in the market are External beam radiation therapy (EBRT) and Brachytherapy.
Chemotherapy- This method uses drugs to attack the tumour cells. These drugs are either given in injection or taken orally. The treatment is done in various cycles and the dose, and the length of treatment depends upon the grade and location of the cancer.
Surgery- There are various surgeries available for the treatment of cervical cancer. These surgeries include laser surgery, cryosurgery, cone biopsy, simple hysterectomy, radical hysterectomy with pelvic lymph node dissection, trachelectomy, and pelvic exenteration.
Targeted Therapy- This therapy attacks the cancer cells without affecting the healthy cells. The drugs target the proteins that control the spread of the cells.
Immunotherapy- This therapy comprises the use of drugs to boost the immunity cells to fight the cancer cells.
Clinical Trials in the Cervical Cancer Treatment Market
There are numerous studies which are currently under trials, some of these ongoing trials are as follows:
- A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer (Last updated in January 2023) - This trial is currently under the phase II of studying the effects of using a drug called Nivolumab in patients with persistent, metastatic, and/ or recurrent cervical cancer. This study is sponsored by National Cancer Institute (NCI), in collaboration with the NRG Oncology. Monoclonal antibodies like Nivolumab can help restrict or completely block the growth of the tumour cells. The study is also studying the possibility of toxic effects that Nivolumab can exhibit.
- Study of Combination Radiation Therapy and Cisplatin, with or without Triapine - This study is currently under the third phase of clinical trial. Triapine might be effective in restricting and preventing the development of cancer cells by blocking the enzymes that help in cell growth. The study is aimed at directing the effectiveness of radiation therapy and cisplatin with the use of triapine in the treatment of cervical cancer.
Key Players in the Global Cervical Cancer Treatment Market
- F. Hoffmann-LA Roche AG
- Merck & Co., Inc.
- GlaxoSmithKline Plc.
- Allergan Inc. (AbbVie, Inc.)
- Biocon Limited
- Pfizer Inc.
- Eli Lilly and Company
- Hologic Inc.
- Qiagen N.V.
- Quest Diagnostics Inc.
- Dickinson and Co.
- Bio-Rad Laboratories Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Stage |
|
| Breakup by Tests |
|
| Breakup by Cell Type |
|
| Breakup by Product Type |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Cervical Cancer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global Cervical Cancer Treatment Market
8.1 Global Cervical Cancer Treatment Market Overview
8.2 Global Cervical Cancer Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Cervical Cancer Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Cervical Cancer Treatment Market Forecast Value (2023-2031)
8.3 Global Cervical Cancer Treatment Market by Stage
8.3.1 Market Overview
8.3.1.1 Stage 0
8.3.1.2 Stage 1
8.3.1.3 Stage 2
8.3.1.4 Stage 3
8.3.1.5 Stage 4
8.4 Global Cervical Cancer Treatment Market by Tests
8.4.1 Market Overview
8.4.1.1 Pap Smear Test Procedure
8.4.1.2 Colposcopy Procedure
8.4.1.3 ECC Procedure
8.4.1.4 Others
8.5 Global Cervical Cancer Treatment Market by Cell Type
8.5.1 Market Overview
8.5.1.1 Adenocarcinoma
8.5.1.2 Squamous Cell Carcinoma
8.5.1.3 Adenosquamous Carcinoma
8.6 Global Cervical Cancer Treatment Market by Product Type
8.6.1 Market Overview
8.6.1.1 Gardasil/Gardasil 9
8.6.1.2 Cervarix
8.6.1.3 Avastin
8.6.1.4 Keytruda
8.6.1.5 Generics
8.6.1.6 Others
8.7 Global Cervical Cancer Treatment Market by Treatment Channel
8.7.1 Public
8.7.2 Private
8.8 Global Cervical Cancer Treatment Market by Region
8.8.1 Market Overview
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 North America Cervical Cancer Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Cervical Cancer Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Cervical Cancer Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Cervical Cancer Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Cervical Cancer Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Cervical Cancer Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 F. Hoffmann-LA Roche AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Merck & Co., Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 GlaxoSmithKline Plc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Allergan Inc. (AbbVie, Inc.)
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Biocon Limited
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Pfizer Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Eli Lilly and Company
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Hologic Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Qiagen N.V.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Quest Diagnostics Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Dickinson and Co.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Bio-Rad Laboratories Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Global Cervical Cancer Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2022, the market attained a value of nearly USD 6.8 billion.
The market is projected to grow at a CAGR of 6.4% during the forecast period of 2023-2031.
The market is estimated to witness healthy growth during the forecast period of 2022-2031 to reach a value of USD 12 billion by 2031.
The growth of the market is driven by factors like rising prevalence of the disease, rapid technological advancements, availability of non-invasive therapies, and rising expenditure on healthcare.
The key trends in the market include rising research and development, along with the rising awareness about the availability and effectiveness of available treatment.
The stages of cervical cancer can be categorised into stage 0, 1, 2, 3, and 4.
The tests used for the diagnosis of the tumour include pap smear test procedure, colposcopy procedure, and ecc procedure, among others.
The market can be divided on the basis of cell type into adenocarcinoma, squamous cell carcinoma, and adenosquamous carcinoma.
The treatment channels can be categorised into public and private.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major players in the market are F. Hoffmann-LA Roche AG, Merck & Co., Inc., GlaxoSmithKline Plc., Allergan Inc. (AbbVie, Inc.), Biocon Limited, Pfizer Inc., Eli Lilly and Company, Hologic Inc., Qiagen N.V., Quest Diagnostics Inc., Dickinson and Co., and Bio-Rad Laboratories Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER